Materials technology company Ceram has announced the publication of a white paper on hydroxyapatite with tailored bioactivity for bone replacement and drug delivery applications.
“Multi-Substituted Hydroxyapatites and the Role They Can Play in Enhanced Bone Replacement Solutions” includes an overview of synthetic HA (and associated structures) for bone replacement and an in-depth report on substituted hydroxyapatite.
Some results from a recently completed study on multi-substituted HA—carried out to determine how mean ionic volume and charge affect yield of crystalline HA—are discussed. The findings are based on computer-controlled wet precipitation production routes under mild conditions that should be scalable.
Ceram’s aim is to work with clients to develop HA with tailored bioactivity, both for bone replacement materials applications and for new drug delivery systems with tailored bio-application requirements.